FIELD: medicine.
SUBSTANCE: present invention relates to the use of cangrelor for the treatment and/or prevention of thrombosis of a bypass or a stent in pediatric patients suffering from congenital heart disease and subjected to bypass surgery or stent implantation.
EFFECT: present invention provides reduction in the risk of thrombotic complications in a vulnerable period after surgery, reducing the total mortality rate.
9 cl, 7 dwg, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING PULMONARY HYPERTENSION | 2012 |
|
RU2599490C2 |
| INTRAVENOUS INTRODUCTION OF CITRULLINE DURING SURGICAL INTERVENTION | 2016 |
|
RU2733738C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING HIGH-PURITY CANGRELOR, AND METHODS FOR PRODUCTION AND USE THEREOF | 2015 |
|
RU2733409C2 |
| METHOD FOR RAPID ASSESSMENT OF FUNCTIONAL SOLVENCY OF SUBCLAVIAN-PULMONARY ANASTOMOSIS IN CHILDREN UNDER 1 YEAR OLD | 2019 |
|
RU2704356C1 |
| PALLIATIVE INFUNDIBULECTOMY WITHOUT CLOSING THE DEFECT OF THE INTERVENTRICULAR SEPTUM BY ACCESSING FROM THE RIGHT ATRIUM WITH SEVERE CYANOTIC CONGENITAL HEART DEFECTS COMBINED WITH HYPOPLASIA OF THE PULMONARY ARTERY SYSTEM IN ELDERLY PATIENTS | 2020 |
|
RU2738458C1 |
| METHOD OF SUPERIMPOSING A SYSTEMIC-PULMONARY SHUNT WITH A SYNTHETIC PROSTHESIS IN PATIENTS WITH PULMONARY ARTERY HYPOPLASIA | 2017 |
|
RU2652754C1 |
| CONSEQUENCES OF LUNG DAMAGE INDUCED BY ARTIFICIAL BLOOD CIRCULATION | 2017 |
|
RU2762593C2 |
| METHOD FOR HYBRID SURGICAL TREATMENT WITH TRANSCATHETER IMPLANTATION OF PULMONARY VALVE WITH TRANSAPICAL ACCESS | 2020 |
|
RU2777182C2 |
| METHOD OF TREATING CONGENITAL HEART DISEASES REQUIRING PROSTHETICS OF A PULMONARY ARTERY, A BIOLOGICAL STENT-CONDUIT FOR ITS IMPLEMENTATION AND A METHOD FOR MANUFACTURING A BIOLOGICAL STENT-CONDUIT | 2019 |
|
RU2721883C1 |
| METHOD OF TREATING OR PREVENTING ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION IN PAST HISTORY | 2016 |
|
RU2707959C2 |
